Corium International (CORI) Cut to Hold at BidaskClub

Corium International (NASDAQ:CORI) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

A number of other brokerages have also recently issued reports on CORI. Zacks Investment Research upgraded Corium International from a “sell” rating to a “hold” rating in a report on Monday, January 22nd. ValuEngine raised Corium International from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. HC Wainwright set a $14.00 price target on Corium International and gave the stock a “buy” rating in a research report on Friday, February 9th. Needham & Company LLC boosted their price target on Corium International from $13.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday, November 20th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $14.00 price target on shares of Corium International in a research report on Friday, December 22nd. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Corium International currently has an average rating of “Buy” and a consensus price target of $12.86.

How to Become a New Pot Stock Millionaire

Shares of Corium International (CORI) opened at $12.23 on Tuesday. The company has a current ratio of 1.40, a quick ratio of 1.34 and a debt-to-equity ratio of 5.91. Corium International has a fifty-two week low of $3.50 and a fifty-two week high of $13.93. The stock has a market capitalization of $441.80, a PE ratio of -7.79 and a beta of 1.50.

Corium International (NASDAQ:CORI) last issued its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.06. Corium International had a negative return on equity of 403.15% and a negative net margin of 148.07%. The business had revenue of $9.32 million during the quarter, compared to analysts’ expectations of $7.48 million. research analysts expect that Corium International will post -1.43 earnings per share for the current fiscal year.

In other Corium International news, major shareholder Perceptive Advisors Llc bought 50,350 shares of the business’s stock in a transaction on Tuesday, January 16th. The shares were bought at an average cost of $11.83 per share, with a total value of $595,640.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Life Sciences Maste Perceptive bought 510,000 shares of the business’s stock in a transaction on Thursday, January 18th. The stock was acquired at an average cost of $12.54 per share, for a total transaction of $6,395,400.00. The disclosure for this purchase can be found here. Insiders own 30.80% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC raised its position in shares of Corium International by 14.0% in the 4th quarter. Renaissance Technologies LLC now owns 96,900 shares of the biopharmaceutical company’s stock valued at $931,000 after purchasing an additional 11,900 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Corium International by 6.0% in the 4th quarter. Geode Capital Management LLC now owns 223,536 shares of the biopharmaceutical company’s stock valued at $2,147,000 after purchasing an additional 12,745 shares in the last quarter. MetLife Investment Advisors LLC acquired a new position in shares of Corium International in the 4th quarter valued at approximately $123,000. Schwab Charles Investment Management Inc. raised its position in shares of Corium International by 47.3% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 49,509 shares of the biopharmaceutical company’s stock valued at $476,000 after purchasing an additional 15,909 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Corium International by 126.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 32,998 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 18,416 shares in the last quarter. 88.58% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Corium International (CORI) Cut to Hold at BidaskClub” was reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.themarketsdaily.com/2018/03/13/corium-international-cori-cut-to-hold-at-bidaskclub.html.

Corium International Company Profile

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

Analyst Recommendations for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply